查詢結果分析
來源資料
相關文獻
- Treatment of Metastatic or Recurrent Gastric Cancer with Weekly 24-hour Infusion of Cisplatin and High-Dose 5-Fluorouracil/Leucovorin in an Outpatient Setting
- 胃癌化學治療之進展
- Rarely Reported Liver Toxicity in Patients Who were Hepatitis B Carrier and Underwent Chemoirradiation for Gastric Cancer
- The Role of Extended Lymphadenectomy and Adjuvant Immunochemotherapy for Gastric Cancer
- 胃癌之化學治療
- Recent Advances in Therapy for Gastric Cancer
- Treatment Outcome in Patients with Locally Advanced Gastric Cancer Receiving Adjuvant Chemoradiotherapy
- A Phase Ⅱ Study of Irinotecan in Combination with Cisplatin as Second-line Chemotherapy in Patients with Metastatic or Locally Advanced Gastric Cancer
- Chemotherapy and Radiotherapy in Gastric Cancer
- 一位智能障礙的胃癌病人接受化學治療之個案管理經驗
頁籤選單縮合
| 題 名 | Treatment of Metastatic or Recurrent Gastric Cancer with Weekly 24-hour Infusion of Cisplatin and High-Dose 5-Fluorouracil/Leucovorin in an Outpatient Setting=以門診接受每週一次24小時輸注Cisplatin高劑量5-Fluorouracil/Leucovorin治療轉移或復發性胃癌病患 |
|---|---|
| 作 者 | 王佐輔; 李啟誠; 朱崧肇; 姚朝元; 高瑞和; | 書刊名 | 慈濟醫學 |
| 卷 期 | 18:6 民95.12 |
| 頁 次 | 頁432-437+467 |
| 分類號 | 415.527 |
| 關鍵詞 | 胃癌; 化學治療; 門診治療; Gastric cancer; Cisplatin; 5-fluorouracil; Chemotherapy; Outpatient setting; |
| 語 文 | 英文(English) |
| 中文摘要 | 目的:目前針對轉移性胃癌病患尚無標準治療。我們評估以門診每週接受一次24小時輸注Cisplatin和高劑量5-fluorouracil/Leucovorin治療轉移性胃癌病患之療效與毒性。病人與方法:從2001年到2005年7月共有21位轉移性胃癌病患接受治療,療程為每週一次24小時?注Cisplatin(25 mg/□)和5-FU (2000 mg/□)Leucovorin (200mg/m□ ),每治療三週後休息一週為一療程,最多進行六個療程。期間規則評估治療效果及毒性。若是病情進展或不可容忍之毒性,則停止治療。結果:21位轉移性胃癌病患中,16位為男性、5位為女性;中位年齡為56歲(21-71)。中位治療週期為4.3個療程。治療整體反應率為33.3%,中位存活期為7.7個月。主要毒性為肝功能指數升高(發生率為52%,其中19%為第三級毒性以上),而消化道及血液毒性皆為輕微。結論:本研究顯示此一門診療程治療轉移性胃癌病患比較以往療程具有相同療效。若考慮治療效果、毒性及方便性來達到增加病患接受度並改善其生活品質,我們認為此療程為一合理的解釋。 |
| 英文摘要 | Objective: These is no general agreement over a standard chemotherapy regimen for metastatic or recurrent gastric cancer. We evaluated, retrospectively, the activity and toxicity of weekly 24-hour infusion of cisplatin with high-dose 5-fluorouacil/leuocovorin (P-HDFL) in an outpatient setting. Materials and Methods: Patients with metastatic or recurrent gastric cancer, treated in an outpatient setting from May 2001 to July 2005, were analyzed retrospectively, The regimen consisted of continuous infusion cisplatin 25 mg/□, 5-fluorouracil 2000 mg/□ and leucovorin 200 mg/□ on day 1, 8 and 15 every 4 weeks. The treatment was continued for a maximum of six cycles unless the disease progressed or intolerable toxicities occurred. Results: Twenty-one patients received this regimen: 16 men and 5 women, median age 56 years (range27-71). A median of 4.3 cycles was administered. Severn of 21 patients (33.3%) achieved an objective partial response. Stable disease was observed in 6 patients (28.6%) and progressive disease in 8 patients (38.1%). The median survival was 7.7 months (95% confidence interval, 6.2-12.8 months). Digestive and hematological toxicities were low and no severe renal insufficiency was observed. The most common toxicity was elevated liver enzymes (1) patients, 52%), of whom three had ≧ grade 3 toxicity: 1 of them died of hepatic failure. Conclusion: Our results who that outpatient P-HDFL therapy leads to fairly comparable outcome with various regimens of 5-fluorouracil/cisplatin. This outpatient regimen could be a reasonable alternative that combines advantages in respect of patient activity, mild to moderate toxicity, convenience of dosing and minor expenditure. |
本系統中英文摘要資訊取自各篇刊載內容。